Aclaris Therapeutics Sells OLUMIANT Royalties And Milestones To OMERS Life Sciences For Up To $31.5M
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics has sold its OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million. The deal includes $26.5 million upfront and up to $5.0 million in milestone payments. This non-dilutive transaction aims to strengthen Aclaris' balance sheet to support its strategic priorities.
July 16, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclaris Therapeutics has sold its OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million. This non-dilutive transaction will provide $26.5 million upfront and up to $5.0 million in milestone payments, strengthening Aclaris' balance sheet to support its strategic priorities.
The sale of OLUMIANT royalties and milestones will provide Aclaris Therapeutics with significant non-dilutive capital. This strengthens the company's balance sheet, allowing it to focus on its strategic priorities without issuing new shares, which is positive for existing shareholders.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100